First Author: P.Nemec CZECH REPUBLIC
Co Author(s): J. Ernest L. Rejmont K. Manethova 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate photodynamic therapy (PDT) and anti-VEGF therapy for juxtafoveal and extrafoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). To examine the 36-month results for patients treated with this combined therapy.
Department of Ophthalmology of the First Faculty of Medicine - Charles University and Central Military Hospital - Prague
Prospective series of 25 eyes with juxtafoveal or subfoveal CNV secondary to AMD. Patients were treated with PDT with verteporfin and next day (period less than 24 hours) 0,5 mg of ranibizumab was injected intravitreally. All patients were naive to treatment. Main outcome measures were visual acuity stabilization (defined as no change or a gain in visual acuity), changes in central retinal thickness (OCT) and retreatment (anti-VEGF only) rate.
At the 36-month follow-up, 44 (88%) of 48 patients had stabilization of visual acuity. 32 patients (64%) had improvement in visual acuity more than 5 letters ETDRS. 4 patients (8%) had excellent improvement in visual acuity (+15 letters ETDRS). Mean improvement in visual acuity (n = 48) was 4,5 letters ETDRS. The average central retinal thickness decreased from 432 um to 246 um (FU 36 (3rd year)). Average number of intravitreal application of ranibizumab at FU 12 was 5,16 (range 3-8), FU 24 3,5 (range 1-5) and FU 36 2,6 (range 0-5) .
The results of this study suggest that combined treatment of PDT with verteporfin and intravitreal ranibizumab may be useful in treating neovascular AMD by reducing retreatment rates and improving visual acuity.